A Multinational, Randomized, Double-Blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer.

Trial Profile

A Multinational, Randomized, Double-Blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Aflibercept (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms VANILLA
  • Most Recent Events

    • 30 Mar 2012 Clinical Trials Registry - India reports trial status as completed.
    • 03 Jul 2010 Final results presented at the 12th World Congress on Gastrointestinal Cancer 2010.
    • 03 Jul 2010 Actual number of patients added.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top